Vivos Therapeutics Secures $5M Bridge Loan, Restructures $4.5M Debt to Boost Liquidity
VVOS sits 44% above its 52-week low of $0.545 on elevated volume (52× avg).
Summary
Vivos Therapeutics announced a critical two-part financing strategy. The company will convert up to $4.5 million of senior debt with Streeterville Capital into equity, extending maturities to 2027. Separately, it secured up to $5 million in new convertible bridge financing from V-Co Investors 4, with $500,000 already funded. These moves are essential to address the company's severe liquidity issues and reduce immediate cash outflows, following its recent "going concern" warning and Nasdaq delisting risk. The bridge note is expected to convert into a planned equity offering by June 30, 2026.
At the time of this announcement, VVOS was trading at $0.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12M. The 52-week trading range was $0.55 to $7.95. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: Wiseek News.